Available to treat adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement PEMAZYRE ® (pemigatinib) is available via a co-pay access program in Australia ...
Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify [email protected] if there are concerns ...
Gallbladder cancer and cholangiocarcinoma are both biliary cancers. They can cause the same symptoms, but causes and treatments can differ. Gallbladder cancer is cancer of the gallbladder, while ...
Gallbladder cancer and cholangiocarcinoma are different types of biliary tract cancer. They affect the same system in the body and cause similar symptoms, but they may require different treatments.
Primary sclerosing cholangitis (PSC) is a rare progressive liver disease that damages bile ducts and significantly increases the risk of bile duct cancer, particularly a type called cholangiocarcinoma ...
Ten years ago, Cholangiocarcinoma was a little known, little understood, rare disease, also known as an orphan cancer. This is no longer the case ever since the Cholangiocarcinoma Foundation was ...
BASKING RIDGE, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for ...
Bile duct cancer, or cholangiocarcinoma, is a rare type of cancer that starts in the bile ducts. Bile ducts are small tubes in your body that carry bile (digestive fluids) from your liver and ...
Bile duct cancer, or cholangiocarcinoma, is a serious concern due to its rapid progression and often mild, easily mistaken ...
Each year, around 8,000 people in the United States receive a diagnosis of bile duct cancer. This means it’s a very rare cancer. Your liver produces bile to help you digest fats by turning them into ...
– Using Invitae's Ciitizen patient-driven data platform, AstraZeneca and the Cholangiocarcinoma Foundation will access lived experience of patients with a rare cancer to drive further research – – ...